Catalent to Commercially Supply Palatin Technologies’ New Bremelanotide FSD Product in Pen Injectors
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has reached a commercial supply agreement with Palatin Technologies, Inc., to support the global commercial product launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD).
Bremelanotide, an on-demand, subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. Phase 3 clinical trials are on-going, with a commercial launch anticipated in 2018.
“We are pleased that Palatin has chosen to partner with Catalent to commercialize this new and innovative treatment,” commented Jonathan Arnold, Catalent’s Vice President and General Manager for Advanced Delivery Technologies. “Catalent provides flexible manufacturing solutions to meet our customers’ unique program requirements, and our expertise in sterile filling, device and delivery technologies, combined with our packaging capabilities, will facilitate bringing this important product to market faster.”
“We selected Catalent as our partner because of their proven expertise in custom sterile manufacturing solutions, and their track record of successful new product introductions,” added Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin. “Catalent provides the infrastructure, technical expertise and flexibility to support commercialization of this novel product.”
The bremelanotide pen devices will be produced at Catalent’s 265,000 sq. ft. Brussels, Belgium site, the company’s flagship sterile fill finish facility, with a syringe-filling capacity of over 100 million units.
Palatin Technologies, Inc., is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Additional information about Palatin is available at www.palatin.com
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
Total Page Views: 1032
